Published in Proc Natl Acad Sci U S A on January 20, 1998
Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proc Natl Acad Sci U S A (1999) 2.87
Mesothelin targeted cancer immunotherapy. Eur J Cancer (2007) 2.54
Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P. Clin Cancer Res (2009) 2.17
Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin. Cancer Immun (2007) 2.00
Immunotoxins for targeted cancer therapy. AAPS J (2006) 1.86
Engineering Customized Cell Sensing and Response Behaviors Using Synthetic Notch Receptors. Cell (2016) 1.82
A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity. Blood (2008) 1.74
scFv antibody: principles and clinical application. Clin Dev Immunol (2012) 1.64
Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers. Clin Cancer Res (2010) 1.59
Discovery of mesothelin and exploiting it as a target for immunotherapy. Cancer Res (2014) 1.48
Mesothelin-targeted agents in clinical trials and in preclinical development. Mol Cancer Ther (2012) 1.47
Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor. Mol Ther (2011) 1.35
A recombinant immunotoxin against the tumor-associated antigen mesothelin reengineered for high activity, low off-target toxicity, and reduced antigenicity. Mol Cancer Ther (2012) 1.27
PAGE-1, an X chromosome-linked GAGE-like gene that is expressed in normal and neoplastic prostate, testis, and uterus. Proc Natl Acad Sci U S A (1998) 1.24
Stromelysin-1 and mesothelin are differentially regulated by Wnt-5a and Wnt-1 in C57mg mouse mammary epithelial cells. BMC Dev Biol (2003) 1.22
Identification of novel human CTL epitopes and their agonist epitopes of mesothelin. Clin Cancer Res (2005) 1.14
Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy. Lung Cancer (2009) 1.13
The role of mesothelin in tumor progression and targeted therapy. Anticancer Agents Med Chem (2013) 1.12
A novel high-affinity human monoclonal antibody to mesothelin. Int J Cancer (2011) 1.06
A novel human monoclonal antibody that binds with high affinity to mesothelin-expressing cells and kills them by antibody-dependent cell-mediated cytotoxicity. Mol Cancer Ther (2009) 1.05
Pentostatin plus cyclophosphamide safely and effectively prevents immunotoxin immunogenicity in murine hosts. Clin Cancer Res (2011) 1.04
Identification of a putative Crf splice variant and generation of recombinant antibodies for the specific detection of Aspergillus fumigatus. PLoS One (2009) 0.98
Mesothelin Immunotherapy for Cancer: Ready for Prime Time? J Clin Oncol (2016) 0.88
Advances in liver cancer antibody therapies: a focus on glypican-3 and mesothelin. BioDrugs (2011) 0.87
Chimeric antigen receptor T-cell therapy for solid tumors. Mol Ther Oncolytics (2016) 0.86
Tumor-specific Ab-mediated targeting of MHC-peptide complexes induces regression of human tumor xenografts in vivo. Proc Natl Acad Sci U S A (2004) 0.86
The orphan nuclear receptor Ear-2 is a negative coregulator for thyroid hormone nuclear receptor function. Mol Cell Biol (2000) 0.85
Targeted coating with antigenic peptide renders tumor cells susceptible to CD8(+) T cell-mediated killing. Mol Ther (2012) 0.85
Preparation of single chain variable fragment of MG(7) mAb by phage display technology. World J Gastroenterol (2001) 0.84
Recombinant Immunotoxin with T-cell Epitope Mutations That Greatly Reduce Immunogenicity for Treatment of Mesothelin-Expressing Tumors. Mol Cancer Ther (2015) 0.83
Mesothelin-targeted immunotherapies for malignant pleural mesothelioma. Ann Cardiothorac Surg (2012) 0.80
Membrane-proximal TRAIL species are incapable of inducing short circuit apoptosis signaling: Implications for drug development and basic cytokine biology. Sci Rep (2016) 0.79
Optimization of Gene Transfection in Murine Myeloma Cell Lines using Different Transfection Reagents. Avicenna J Med Biotechnol (2010) 0.79
Expression and identification of recombinant soluble single-chain variable fragment of monoclonal antibody MC3. World J Gastroenterol (2002) 0.78
Novel immunocytokine IL12-SS1 (Fv) inhibits mesothelioma tumor growth in nude mice. PLoS One (2013) 0.78
Generation and Characterization of an scFv Directed against Site II of Rabies Glycoprotein. Biotechnol Res Int (2011) 0.77
Novel Antibody Therapeutics Targeting Mesothelin In Solid Tumors. Clin Cancer Drugs (2016) 0.76
Chicken scFvs with an Artificial Cysteine for Site-Directed Conjugation. PLoS One (2016) 0.75
Investigational approaches for mesothelioma. Front Oncol (2011) 0.75
Controlling tumor-derived and vascular endothelial cell growth: role of the 4Ff2 cell surface antigen. Am J Pathol (2001) 0.75
Furin-dependent CCL17-fused recombinant toxin controls HTLV-1 infection by targeting and eliminating infected CCR4-expressing cells in vitro and in vivo. Retrovirology (2015) 0.75
Novel systemic therapy against malignant pleural mesothelioma. Transl Lung Cancer Res (2017) 0.75
Genetic immunization is a simple method for eliciting an immune response. Nature (1992) 5.30
Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci U S A (1996) 4.49
Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science (1996) 3.82
Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med (1993) 3.18
A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin. Nature (1989) 2.13
Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization. Proc Natl Acad Sci U S A (1996) 2.01
Molecular evolution of proteins on filamentous phage. Mimicking the strategy of the immune system. J Biol Chem (1992) 1.95
B3(Fv)-PE38KDEL, a single-chain immunotoxin that causes complete regression of a human carcinoma in mice. Proc Natl Acad Sci U S A (1991) 1.89
Monoclonal antibody K1 reacts with epithelial mesothelioma but not with lung adenocarcinoma. Am J Surg Pathol (1992) 1.85
A method for increasing the yield of properly folded recombinant fusion proteins: single-chain immunotoxins from renaturation of bacterial inclusion bodies. Anal Biochem (1992) 1.78
Characterization of the antigen (CAK1) recognized by monoclonal antibody K1 present on ovarian cancers and normal mesothelium. Cancer Res (1992) 1.73
Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol (1997) 1.57
A novel cytokine exhibiting megakaryocyte potentiating activity from a human pancreatic tumor cell line HPC-Y5. J Biol Chem (1994) 1.51
Engineering antibody Fv fragments for cancer detection and therapy: disulfide-stabilized Fv fragments. Nat Biotechnol (1996) 1.49
Isolation and characterization of the C and D proteins coded by gene IX and gene VI in the filamentous bacteriophage fl and fd. J Biol Chem (1980) 1.42
In vivo protective anti-HIV immune responses in non-human primates through DNA immunization. J Med Primatol (1996) 1.29
Immunization with DNA. J Immunol Methods (1994) 1.22
Treatment of advanced solid tumors with immunotoxin LMB-1: an antibody linked to Pseudomonas exotoxin. Nat Med (1996) 1.19
Improved binding and antitumor activity of a recombinant anti-erbB2 immunotoxin by disulfide stabilization of the Fv fragment. J Biol Chem (1994) 1.14
Stabilization of the Fv fragments in recombinant immunotoxins by disulfide bonds engineered into conserved framework regions. Biochemistry (1994) 1.06
Immunotoxins against cancer. Biochim Biophys Acta (1994) 1.06
Antitumor activity and pharmacokinetics in mice of a recombinant immunotoxin containing a disulfide-stabilized Fv fragment. Cancer Res (1994) 0.96
Isolation of anti-mesothelin antibodies from a phage display library. Mol Immunol (1997) 0.88
Cytotoxic and antitumor activity of a recombinant immunotoxin composed of disulfide-stabilized anti-Tac Fv fragment and truncated Pseudomonas exotoxin. Int J Cancer (1994) 0.88
Phage display of disulfide-stabilized Fv fragments. J Immunol Methods (1995) 0.87
An artificial immune system for making antibodies. Behring Inst Mitt (1992) 0.85
Cloning and expression of the recombinant FAb fragment of monoclonal antibody K1 that reacts with mesothelin present on mesotheliomas and ovarian cancers. Int J Cancer (1997) 0.83
The Rous sarcoma virus long terminal repeat is a strong promoter when introduced into a variety of eukaryotic cells by DNA-mediated transfection. Proc Natl Acad Sci U S A (1982) 20.55
Cyclic AMP receptor protein of E. coli: its role in the synthesis of inducible enzymes. Proc Natl Acad Sci U S A (1970) 13.26
Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem (1993) 10.95
Pleiotropic deficiency of carbohydrate utilization in an adenyl cyclase deficient mutant of Escherichia coli. Biochem Biophys Res Commun (1969) 9.20
Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell (1986) 8.53
Cyclic adenosine 5'-monophosphate in Escherichia coli. Bacteriol Rev (1976) 7.55
Regulation of beta-galactosidase synthesis in Escherichia coli by cyclic adenosine 3',5'-monophosphate. J Biol Chem (1968) 7.54
Cyclic adenosine monophosphate in bacteria. Science (1970) 7.53
Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A (1987) 7.38
Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol (1999) 6.62
Direct visualization of binding, aggregation, and internalization of insulin and epidermal growth factor on living fibroblastic cells. Proc Natl Acad Sci U S A (1978) 6.59
Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci U S A (1987) 5.65
Identification of a functional promoter in the long terminal repeat of Rous sarcoma virus. Cell (1980) 5.51
Restoration of several morphological characteristics of normal fibroblasts in sarcoma cells treated with adenosine-3':5'-cyclic monphosphate and its derivatives. Proc Natl Acad Sci U S A (1971) 5.31
Dansylcadaverine inhibits internalization of 125I-epidermal growth factor in BALB 3T3 cells. J Biol Chem (1980) 5.24
Structure of the promoter for chicken alpha 2 type I collagen gene. Proc Natl Acad Sci U S A (1981) 4.89
In vitro transcription of the gal operon requires cyclic adenosine monophosphate and cyclic adenosine monophosphate receptor protein. J Biol Chem (1971) 4.58
Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci U S A (1996) 4.49
Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci U S A (1987) 4.43
Localization of the src gene product of the Harvey strain of MSV to plasma membrane of transformed cells by electron microscopic immunocytochemistry. Cell (1980) 4.35
Cell surface protein partially restores morphology, adhesiveness, and contact inhibition of movement to transformed fibroblasts. Proc Natl Acad Sci U S A (1976) 4.32
Localization of the ASV src gene product to the plasma membrane of transformed cells by electron microscopic immunocytochemistry. Cell (1979) 4.30
Cyclic 3'5-AMP: stimulation of beta-galactosidase and tryptophanase induction in E. coli. Biochem Biophys Res Commun (1968) 4.16
Identification of two lysosomal membrane glycoproteins. J Cell Biol (1985) 4.08
Characterization and sequence of the promoter region of the human epidermal growth factor receptor gene. Proc Natl Acad Sci U S A (1985) 4.08
Epidermal-growth-factor-dependent transformation by a human EGF receptor proto-oncogene. Science (1987) 3.93
Collection of insulin, EGF and alpha2-macroglobulin in the same patches on the surface of cultured fibroblasts and common internalization. Cell (1978) 3.90
The receptosome: an intermediate organelle of receptor mediated endocytosis in cultured fibroblasts. Cell (1980) 3.88
Regulation of inducible enzyme synthesis in Escherichia coli by cyclic adenosine 3', 5'-monophosphate. J Biol Chem (1969) 3.86
Levels of translatable mRNAs for cell surface protein, collagen precursors, and two membrane proteins are altered in Rous sarcoma virus-transformed chick embryo fibroblasts. Proc Natl Acad Sci U S A (1977) 3.80
Lac DNA, RNA polymerase and cyclic AMP receptor protein, cyclic AMP, lac repressor and inducer are the essential elements for controlled lac transcription. Nat New Biol (1971) 3.79
The collagen gene: evidence for its evolutinary assembly by amplification of a DNA segment containing an exon of 54 bp. Cell (1980) 3.66
Promoter region of the human Harvey ras proto-oncogene: similarity to the EGF receptor proto-oncogene promoter. Science (1985) 3.59
Cyclic AMP levels in fibroblasts: relationship to growth rate and contact inhibition of growth. Biochem Biophys Res Commun (1971) 3.58
Cyclic AMP regulates catabolite and transient repression in E. coli. Nature (1969) 3.42
Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science (1992) 3.41
Glucose depletion accounts for the induction of two transformation-sensitive membrane proteinsin Rous sarcoma virus-transformed chick embryo fibroblasts. Proc Natl Acad Sci U S A (1977) 3.26
Regulation of lac mRNA synthesis in a soluble cell-free system. Nat New Biol (1971) 3.25
Isolation and characterization of myosin from cloned mouse fibroblasts. Proc Natl Acad Sci U S A (1972) 3.24
Isolation and genetic characterization of human KB cell lines resistant to multiple drugs. Somat Cell Mol Genet (1985) 3.23
Human multidrug-resistant cell lines: increased mdr1 expression can precede gene amplification. Science (1986) 3.22
Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells. Proc Natl Acad Sci U S A (1986) 3.19
A key role of starburst amacrine cells in originating retinal directional selectivity and optokinetic eye movement. Neuron (2001) 3.18
Reduced drug accumulation in multiply drug-resistant human KB carcinoma cell lines. Cancer Res (1985) 3.15
The human multidrug resistance (mdr1) gene. cDNA cloning and transcription initiation. J Biol Chem (1987) 3.13
Effect of adenosine 3',5'-monophosphate analogues on the activity of the cyclic adenosine 3',5'-monophosphate receptor in Escherichia coli. J Biol Chem (1972) 3.08
The major cell surface glycoprotein of chick embryo fibroblasts is an agglutinin. Proc Natl Acad Sci U S A (1975) 3.06
Amplification and enhanced expression of the epidermal growth factor receptor gene in A431 human carcinoma cells. Science (1984) 3.06
Microfilament bundles and cell shape are related to adhesiveness to substratum and are dissociable from growth control in cultured fibroblasts. Cell (1977) 2.99
Multiple drug-resistant human KB carcinoma cells independently selected for high-level resistance to colchicine, adriamycin, or vinblastine show changes in expression of specific proteins. J Biol Chem (1986) 2.93
Functional domains of Pseudomonas exotoxin identified by deletion analysis of the gene expressed in E. coli. Cell (1987) 2.93
The role of the lac promotor locus in the regulation of beta-galactosidase synthesis by cyclic 3',5'-adenosine monophosphate. Proc Natl Acad Sci U S A (1968) 2.92
The visualization of fluorescent proteins in living cells by video intensification microscopy (VIM). Cell (1978) 2.89
HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry (1998) 2.87
Regulation of cell growth by cyclic adenosine 3',5'-monophosphate. Effect of cell density and agents which alter cell growth on cyclic adenosine 3',5'-monophosphate levels in fibroblasts. J Biol Chem (1972) 2.85
Multiple-drug resistance in human cancer. N Engl J Med (1987) 2.76
Adenovirus-induced release of epidermal growth factor and pseudomonas toxin into the cytosol of KB cells during receptor-mediated endocytosis. Cell (1983) 2.74
Effect of Rho on transcription of bacterial operons. Nat New Biol (1973) 2.74
Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med (2001) 2.65
The multidrug transporter, a double-edged sword. J Biol Chem (1988) 2.61
Selective killing of HIV-infected cells by recombinant human CD4-Pseudomonas exotoxin hybrid protein. Nature (1988) 2.55
Fluorescent cellular indicators are extruded by the multidrug resistance protein. J Biol Chem (1993) 2.52
Induction of two transformation-sensitive membrane polypeptides in normal fibroblasts by a block in glycoprotein synthesis or glucose deprivation. Cell (1977) 2.52
Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium. Int J Cancer (1992) 2.50
Unusual features in the nucleotide sequence of a cDNA clone derived from the common region of avian sarcoma virus messenger RNA. Proc Natl Acad Sci U S A (1980) 2.45
ATP-dependent transport of vinblastine in vesicles from human multidrug-resistant cells. Proc Natl Acad Sci U S A (1988) 2.44
alpha-Galactosidase A deficient mice: a model of Fabry disease. Proc Natl Acad Sci U S A (1997) 2.43
Morphologic characterization of the pathway of transferrin endocytosis and recycling in human KB cells. Proc Natl Acad Sci U S A (1984) 2.42
Amines inhibit the clustering of alpha2-macroglobulin and EGF on the fibroblast cell surface. Nature (1979) 2.41
Clostridium barkeri sp. n. J Bacteriol (1972) 2.38
Unusual methylation pattern of the alpha 2 (l) collagen gene. Cell (1982) 2.36
Human epidermal growth factor receptor cDNA is homologous to a variety of RNAs overproduced in A431 carcinoma cells. Nature (1984) 2.36
P-glycoprotein and multidrug resistance. Curr Opin Genet Dev (1996) 2.33
Genetic analysis of the multidrug transporter. Annu Rev Genet (1995) 2.29
Localization of multidrug resistance-associated DNA sequences to human chromosome 7. Somat Cell Mol Genet (1986) 2.27
Quantitative determination of the lateral diffusion coefficients of the hormone-receptor complexes of insulin and epidermal growth factor on the plasma membrane of cultured fibroblasts. Proc Natl Acad Sci U S A (1978) 2.26
Mesothelin is not required for normal mouse development or reproduction. Mol Cell Biol (2000) 2.24
alpha 2-macroglobulin adsorbed to colloidal gold: a new probe in the study of receptor-mediated endocytosis. J Cell Biol (1981) 2.19
Characterization of epidermal growth factor receptor gene expression in malignant and normal human cell lines. Proc Natl Acad Sci U S A (1984) 2.18
Isolation and characterization of overlapping genomic clones covering the chicken alpha 2 (type I) collagen gene. Proc Natl Acad Sci U S A (1980) 2.18
A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin. Nature (1989) 2.13
Single cell analysis of daunomycin uptake and efflux in multidrug-resistant and -sensitive KB cells: effects of verapamil and other drugs. Cancer Res (1986) 2.12
Pseudomonas exotoxin contains a specific sequence at the carboxyl terminus that is required for cytotoxicity. Proc Natl Acad Sci U S A (1990) 2.12
Down-regulation of the epidermal growth factor receptor in KB cells is due to receptor internalization and subsequent degradation in lysosomes. Proc Natl Acad Sci U S A (1984) 2.11
Inhibition of VSV binding and infectivity by phosphatidylserine: is phosphatidylserine a VSV-binding site? Cell (1983) 2.11
Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein. Proc Natl Acad Sci U S A (1997) 2.10
ACTH receptors in the adrenal: specific binding of ACTH-125I and its relation to adenyl cyclase. Proc Natl Acad Sci U S A (1970) 2.09
Binding of the Sp1 transcription factor by the human Harvey ras1 proto-oncogene promoter. Science (1986) 2.08
Membrane vesicles from multidrug-resistant human cancer cells contain a specific 150- to 170-kDa protein detected by photoaffinity labeling. Proc Natl Acad Sci U S A (1986) 2.08
Use of recombinant plasmids to characterize collagen RNAs in normal and transformed chick embryo fibroblasts. J Biol Chem (1979) 2.07
Processing of Pseudomonas exotoxin by a cellular protease results in the generation of a 37,000-Da toxin fragment that is translocated to the cytosol. J Biol Chem (1990) 2.04
Regulation of cell motility by cyclic AMP. Nature (1972) 2.03
Correlation between splicing sites within an intron and their sequence complementarity with U1 RNA. Cell (1980) 2.02
Molecular cloning and characterization of a human DNA binding factor that represses transcription. Cell (1989) 2.00
Certain calcium channel blockers bind specifically to multidrug-resistant human KB carcinoma membrane vesicles and inhibit drug binding to P-glycoprotein. J Biol Chem (1987) 1.99
Repression of beta-galactosidase synthesis by glucose in phosphotransferase mutants of Escherichia coli. Repression in the absence of glucose phosphorylation. J Biol Chem (1969) 1.99
High incidence of amplification of the epidermal growth factor receptor gene in human squamous carcinoma cell lines. Cancer Res (1986) 1.98
Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol (2000) 1.95
Activation of transcription at specific promoters by glycerol. J Biol Chem (1974) 1.95
Characterization of a major fibroblast cell surface glycoprotein. Biochemistry (1977) 1.92